SUO

American Urological Association Releases Salvage Therapy for Prostate Cancer Guideline

Retrieved on: 
Thursday, February 29, 2024
Therapy, Recurrence, Salvage therapy, Prostate cancer, Professor, ASTRO, Quality of life, Metastasis, Patient, Radiation, Risk, Society, University, AUA, SUO, Guideline, MPH, American Urological Association, Radiation therapy, Panel, Partnership, Medical imaging

BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.

Key Points: 
  • BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.
  • Understanding the evaluation and appropriate use of salvage therapies for patients with biochemical recurrence is a critical area of prostate cancer care.
  • “Thanks to the incredible expertise of the entire Panel, this guideline helps provide a roadmap that combines the latest advancements with thoughtful recommendations, empowering patients and clinicians alike.”
    This guideline has 30 recommendations and is a useful reference for effective evidence-based care related to salvage therapy for prostate cancer.
  • Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy.

AUA, SUO Release Amendment to Non-Muscle Invasive Bladder Cancer Guideline

Retrieved on: 
Wednesday, January 24, 2024
Death, Guideline, Woman, Patient, American Urological Association, Bladder cancer, Partnership, Society, Combination, Diagnosis, BCG, Cystoscopy, Urine, Disease, AUA, SUO, NMIBC, Dietary supplement

BALTIMORE, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline amendment for the diagnosis and treatment of non-muscle invasive bladder cancer.

Key Points: 
  • BALTIMORE, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline amendment for the diagnosis and treatment of non-muscle invasive bladder cancer.
  • Bladder cancer continues to be a significant health issue in the United States, with non-muscle invasive bladder cancer (NMIBC) accounting for approximately 75% of the estimated 82,000 new cases diagnosed in 2023.
  • “One of the fastest growing spaces in Urologic Oncology is in the treatment of non-muscle invasive bladder cancer,” said Dr. Jeffrey M. Holzbeierlein, SUO president and chair for the guideline amendment.
  • Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment.

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Retrieved on: 
Thursday, November 30, 2023
Chills, Fever, CIS, Carcinoma, Fatigue, Headache, Urinary bladder, Therapy, Cancer, Society, Urination, BCG, Neoplasm, System, SUO, Bacillus, Patient, NMIBC, Pharmaceutical industry

The data will be featured during a poster session at the 24th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Washington, D.C. from November 28, 2023 through December 1, 2023.

Key Points: 
  • The data will be featured during a poster session at the 24th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Washington, D.C. from November 28, 2023 through December 1, 2023.
  • The patient who did not achieve HGRFS was dosed at 10KE, the lowest dose of TARA-002 offered in the trial.
  • Additional details on the trial design will be featured in a Trial in Progress poster at the SUO meeting.
  • A copy of the SUO posters will be available in the Events and Presentations section of the Company’s website: https://ir.protaratx.com .

Christopher M. Pieczonka, M.D., Named CEO of Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
Wednesday, December 13, 2023
Oncology, Health, Hospitals, Practice Management, Health Technology, Other Health, General Health, SUNY, Corporation, Research, Executive, American Urological Association, Clinical research, Patient, ASCO, AUA, NMS, A.M.P, Hospital, Society, SUO, Publication, Center of excellence, Pharmaceutical industry, Nursing, Central New York

Associated Medical Professionals of NY is a leading multi-specialty practice spanning 19 locations in Central New York, including ten offices and nine hospitals.

Key Points: 
  • Associated Medical Professionals of NY is a leading multi-specialty practice spanning 19 locations in Central New York, including ten offices and nine hospitals.
  • is an affiliate of U.S. Urology Partners , one of the largest independent providers of urological and specialty related services in the nation, which is backed by NMS Capital .
  • Corina Tracy, Chief Executive Officer of U.S. Urology Partners , stated, “I am excited to announce that Dr. Christopher Pieczonka has assumed the role of Chief Executive Officer of Associated Medical Professionals of NY.
  • , stated, “I am both honored and humbled to take on the new role of CEO of Associated Medical Professionals.

CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Tuesday, December 5, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, BCG, Woman, Food, NMIBC, BCAN, Carcinoma, Breakthrough therapy, Disease, Bladder cancer, Patient, Fast track (FDA), Caregiver, Cancer, SUO, Society, Bacillus, Pharmaceutical industry

CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.

Key Points: 
  • CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.
  • “Receiving both FDA Fast Track and Breakthrough Therapy Designation is an important milestone in the development of cretostimogene grenadenorepvec and for patients with bladder cancer who urgently need more therapeutic options,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology.
  • CG Oncology looks forward to working with the FDA to advance cretostimogene grenadenorepvec as a potential backbone therapy in bladder cancer.
  • “The Bladder Cancer Advocacy Network (BCAN) is grateful for the expedited review of this potential treatment option for bladder cancer patients with high-risk BCG-unresponsive NMIBC.

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Retrieved on: 
Friday, December 1, 2023
Oncology, Medical Supplies, Health, Health Technology, Clinical Trials, Biotechnology, Prostate, Research, Magnetic resonance imaging, Pathology, University, PSA, Risk, Urology, Patient, Prostate cancer, Prostatectomy, Prognosis, Risk assessment, MRI, GRID, Physician, SUO, Society, HIV disease progression rates, Biopsy, Medical imaging

Assessment with the Decipher Prostate Genomic Classifier and biological insights from the Decipher Genomic Resource for Intelligent Discovery (GRID) research tool indicated that Decipher scoring was associated with grade progression, but not volume progression, of prostate cancer.

Key Points: 
  • Assessment with the Decipher Prostate Genomic Classifier and biological insights from the Decipher Genomic Resource for Intelligent Discovery (GRID) research tool indicated that Decipher scoring was associated with grade progression, but not volume progression, of prostate cancer.
  • “We developed the Decipher Prostate Genomic Classifier to provide actionable information that helps guide patient care,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.
  • “The data presented at SUO 2023 show how users of our test, conducting prospective research on their own patients, affirm the utility of Decipher in real-world settings.
  • We are very grateful for the work conducted by these clinician-scientists on behalf of the entire prostate cancer research community.”

Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Retrieved on: 
Thursday, November 30, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, BCG, Safety, NMIBC, University of Pennsylvania, Carcinoma, Aes, Risk, Disease, Clinical trial, Bladder cancer, Patient, Abstract, FDA, Therapy, University, Mayo Clinic, Recurrence, SUO, Society, Pharmaceutical industry, Urology

The fully-enrolled trial of 116 patients with BCG-unresponsive NMIBC is taking place across North America and the Asia-Pacific region.

Key Points: 
  • The fully-enrolled trial of 116 patients with BCG-unresponsive NMIBC is taking place across North America and the Asia-Pacific region.
  • The primary endpoint of the study is CR at any time, with duration of response measured as a secondary endpoint.
  • No grade 3 or higher AEs related to cretostimogene grenadenorepvec were observed and there were no treatment discontinuations due to AEs.
  • “Our goal is to transform the treatment landscape for patients with bladder cancer, and these results reinforce our commitment to developing bladder-sparing therapeutics to improve patient outcomes and quality of life.”

New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)

Retrieved on: 
Wednesday, November 29, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, BCG, Vice, Safety, Food, NMIBC, Toxicity, Carcinoma in situ, Carcinoma, Clinical trial, HG, Patient, Probability, Ferring Pharmaceuticals, CIS, Cystectomy, Mayo Clinic, EST, Recurrence, SUO, Society, HIV disease progression rates, Pharmaceutical industry

ADSTILADRIN is the first and only intravesical gene therapy approved by the U.S. Food and Drug Administration (FDA) in this patient population.

Key Points: 
  • ADSTILADRIN is the first and only intravesical gene therapy approved by the U.S. Food and Drug Administration (FDA) in this patient population.
  • Patients without evidence of HG recurrence were allowed to continue ADSTILADRIN treatment every three months as part of an ongoing follow-up analysis.
  • Among patients who continued treatment after the 12-month Phase 3 period, 25.5% (14/55 patients) remained HG recurrence-free at 36 months following the start of treatment.
  • At 36 months, the KM-estimated cystectomy-free survival (95% CI) was 53.8% (43.3%, 63.1%), and the three-year overall survival was 90.4% (82.3%, 94.9%).

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Retrieved on: 
Wednesday, November 22, 2023
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, American Cancer Society, PSA, Disease, Urology, Patient, Prostate cancer, MAST, Neoplasm, Prostate-specific antigen, Physician, SUO, Society, Biopsy, Medical imaging, Lace

Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.
  • Collectively, the posters will report data from more than 60,000 patients.
  • The American Cancer Society estimates that there will be nearly 290,000 new cases of prostate cancer in the U.S. this year.
  • An ongoing challenge in the management of prostate cancer is distinguishing between patients whose tumors require careful monitoring, known as active surveillance, and those who require intervention.

CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023

Retrieved on: 
Tuesday, November 14, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, BCG, Mayo Clinic, Patient, Society, Omni Shoreham Hotel, SUO, NMIBC

BOND-003 ( NCT04452591 ) is a single-arm, open-label, Phase 3 clinical trial evaluating cretostimogene grenadenorepvec as monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

Key Points: 
  • BOND-003 ( NCT04452591 ) is a single-arm, open-label, Phase 3 clinical trial evaluating cretostimogene grenadenorepvec as monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
  • The study enrolled 116 patients with BCG-unresponsive NMIBC across North America and the Asia-Pacific region.
  • The primary endpoint of the study is complete response (CR) at any time, with duration of response measured as a secondary endpoint.
  • Details of the oral presentation are as follows:
    Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ